# Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments

> **NCT07468071** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer
- Advanced Solid Tumors Harboring the KRAS G12C Mutation

## Interventions

- **DRUG:** Opnurasib
- **DRUG:** TNO155
- **DRUG:** trametinib
- **BIOLOGICAL:** cetuximab
- **BIOLOGICAL:** tislelizumab

## Key facts

- **NCT ID:** NCT07468071
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2029-06-15
- **Final completion:** 2029-09-17
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07468071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07468071, "Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07468071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*